Heinrich-Heine-University
Düsseldorf, North Rhine-Westphalia, 40225, Germany
NCT Number: NCT01412320
Purpose of the study is to characterize the potential acute and long-term improvement of dietary flavanols on vascular function in patients with end-stage renal disease (ESRD).
Patients will twice daily receive either a flavanol-poor or a flavanol-rich drink. In a double blind, placebo-controlled crossover study the safety, efficacy and acute beneficial effects of flavanol ingestion will be assessed in 10 patients with ESRD. In a 30 day long-term, double blind, placebo-controlled parallel study the chronic effects of dietary flavanols on vascular function in 52 patients with ESRD will be evaluated.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
dissolved in water twice daily
Time frame: 30 days
To study the effect of flavanols on flow mediated dilation of the brachial artery after 5 minutes of forearm ischemia and reperfusion in patients with ESRD
Klinik für Kardiologie, Pneumologie und Angiologie
Other
The Impact of Dietary Flavanols on Cardiovascular Dysfunction in End-stage Renal Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06515899
Chronic Disease, Disease Attributes
Stevenage, Hertfordshire, United Kingdom
View Trial DetailsNCT03719339
Acute Cellular Graft Rejection, Antibody-mediated Rejection
La Jolla, California, United States
View Trial DetailsNCT04817774
Chronic Disease, Disease Attributes
Leuven, Belgium
View Trial DetailsNCT02984124
Chronic Disease, Disease Attributes
Chapel Hill, North Carolina, United States
View Trial Details